Prev Next
CancerNext®
powered by Ambry Genetics®
Individuals with a personal or family history which is suggestive of hereditary cancer may benefit from CancerNext® genetic testing.
The CancerNext® panel comprises 36 genes associated with increased lifetime risk for at least one of 8 major hereditary cancers such as breast, colorectal, ovarian and uterine among others.
Actionable Pan-Cancer Approach
The panel is comprised of actionable biomarkers, with management guidelines available for most targets.
Indications Detected
Pan-cancer
breast, colorectal, ovarian, uterine, pancreatic, prostate, melanoma, stomach + other cancers
Sample Type(s)
Whole Blood
Saliva
Turnaround Time
14-21 days from receipt of specimen
Features
36 gene panel
Increases detection rate of patients with hereditary cancer by up to 10% compared to smaller gene panels
National Comprehensive Cancer Network (NCCN) Management Guielines® for most panel content
Next Generation Sequencing (NGS) or Sanger Sequencing of all coding domains, plus flanking 5’ and 3’ ends of all introns and untranslated regions
Gross deletion/duplication analysis is performed for the covered exons and untranslated regions of all sequenced genes using read-depth from NGS data with confirmatory MPLA and/or chromosomal microarray
For full test description please visit Ambry’s website
